Allurion Technologies Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Matt Taylor - Jefferies - Analyst : Hi, good morning. Thanks for taking the question. So I wanted to follow up on these interesting results that you presented looking at using the balloons with the low dose GLP-1s. I was wondering if you could just expand on some of the reasons why you think the results were so good there in terms of both weight loss and the lean muscle or lean mass gain?

Question: Matt Taylor - Jefferies - Analyst : Great, thank you. And I just wanted to ask you a separate question on the 2025 guidance of $30 million. Could you talk about any key assumptions in there in terms of volumes pricing, France, anything that might help us understand how you're looking to get to the $30 million for the year? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 26, 2025 / 12:30PM, ALUR.N - Q4 2024 Allurion Technologies Inc Earnings Call

Question: Matt Taylor - Jefferies - Analyst : And one final one for me, I guess, you talked about the potential for the US approval in 2026. What are some of the guide posts that you would point investors to track your progress in the US along the regulatory pathway this year?

Question: Matt Taylor - Jefferies - Analyst : Great, thank you so much.

Question: Joshua Jennings - TD Cowen - Analyst : Hi, good morning, thanks for taking the question. Wanted to just follow up on your call out of the momentum in the fourth quarter in these terms of procedure volume growth for GLP-1s are relatively mature is I just wanted to ask about seeing the end of the first quarter but are you seeing that momentum continue? I mean that's what we're assuming. But just wanted to hear any commentary you can share just on first quarter trends.

Question: Joshua Jennings - TD Cowen - Analyst : Excellent. And you presented publicly the case series for the combo therapy running on and GLP-1s and the VCS platform. And it sounds like in your remarks today that that approach is already being implemented by bariatric surgeons internationally. Just was hoping maybe you could help us think through the combo approaches potential before some of the clinical development -- before the clinical development program builds that you're planning and just have one follow up.

Question: Joshua Jennings - TD Cowen - Analyst : Excellent. And just on the clinical development program and the perspective studies. Any, I know it's still it's very early, but can you share any high level color on clinical trial design or just when do you expect to have readouts where those prospective study results could have a bigger impact in terms of driving this commo therapy approach? Thanks for taking the question.

Question: Joshua Jennings - TD Cowen - Analyst : Appreciate that chat too, thanks.

Question: Jason Wittes - ROTH Capital - Analyst : Hi, thanks for checking the questions. In terms of the B2B2C roll out, has that been fully implemented? Or is that something that's going to take place throughout the remainder of 2025?

Question: Jason Wittes - ROTH Capital - Analyst : Okay great. And in terms of, you know, the patients that you're getting traction for in the regions you're getting traction for you mentioned that the more mature markets that is the more mature markets with GLP-1s are seeing it sounds like the most growth or any metrics you can provide in terms of what regions those are and you know how they're performing?

Question: Jason Wittes - ROTH Capital - Analyst : Oh great. That's helpful. Let me one last question on sort of OpEx the reduction are all those changes in place or is there going to be continued reductions throughout the rest of this year? How do we think about modeling those OpEx changes for the year?

Question: Jason Wittes - ROTH Capital - Analyst : Got it. Great I'll throw back. I'll jump back and you. Thank you.

Question: Tina Kaye - Chardon - Analyst : Thank you. Just wondering if you provide a little more granularity about the cadence of the revenue expect to get to $30 million for the full year?

Question: Tina Kaye - Chardon - Analyst : And when do you expect to see sort of a meaning meaningful contribution from France start to show up in revenue?

Question: Tina Kaye - Chardon - Analyst : Okay. And then I guess similarly, in terms of the gross margin, obviously down in Q4. But you're expecting year-over-year improvement so again how does that look sort of throughout the year in terms of building back to that number?

Question: Tina Kaye - Chardon - Analyst : Okay and then how does the timing of launching the smaller balloon impact margin?

Question: Tina Kaye - Chardon - Analyst : Okay great. That's helpful thanks.